A case of synchronous high‐grade cervical intraepithelial neoplasia and metastatic squamous cell carcinomas of unknown primary in rectum

2021 ◽  
Author(s):  
Syunsuke Orisaka ◽  
Mitsuhiro Nakamura ◽  
Takeshi Obata ◽  
Junpei Iwadare ◽  
Yasunari Mizumoto ◽  
...  
Keyword(s):  
Cervical Intraepithelial Neoplasia ◽  
Squamous Cell ◽  
Intraepithelial Neoplasia ◽  
Squamous Cell Carcinomas ◽  
Unknown Primary ◽  
High Grade

scholarly journals Expression of FasL in squamous cell carcinomas of the cervix and cervical intraepithelial neoplasia and its role in tumor escape mechanism

Cancer ◽  
2006 ◽  
Vol 106 (5) ◽  
pp. 1065-1077 ◽  
Author(s):  
Ramy Ibrahim ◽  
Helen Frederickson ◽  
Allyson Parr ◽  
Yvona Ward ◽  
Joel Moncur ◽  
...  
Keyword(s):  
Cervical Intraepithelial Neoplasia ◽  
Squamous Cell ◽  
Intraepithelial Neoplasia ◽  
Squamous Cell Carcinomas ◽  
Tumor Escape ◽  
Escape Mechanism ◽  
Tumor Escape Mechanism

Utilization of P16 in Head and Neck Cytology and Surgical Specimens After the Release of CAP Guidelines

2020 ◽  
Vol 154 (Supplement_1) ◽  
pp. S22-S22
Author(s):  
H Laharwani ◽  
V Manucha ◽  
G Jefferson ◽  
L Jackson
Keyword(s):  
Head And Neck ◽  
Squamous Cell ◽  
Squamous Cell Carcinomas ◽  
Common Reason ◽  
Unknown Primary ◽  
Hpv Testing ◽  
Neck Masses ◽  
P16 Immunohistochemistry ◽  
Hpv Status ◽  
Wrong Site

Abstract Introduction/Objective HPV-positive oropharyngeal squamous cell carcinoma is biologically and clinically unique and has a survival advantage over other head and neck squamous cell carcinomas. In December 2017 College of American Pathologist published guidelines for testing HPV status in head and neck cancer. It was recommended that pathologists perform HR-HPV testing on head and neck squamous cell carcinomas from all patients with known oropharyngeal SCC not previously tested for HR-HPV, with suspected oropharyngeal SCC, or with metastatic SCC of unknown primary. The aim of this study was to determine the compliance of pathologists following the CAP guidelines. Methods Cases that underwent HPV testing using p16 immunohistochemistry for the years 2017 and 2019 were retrieved. Based on the guidelines, p16 testing was designated as “indicated” or “not indicated”. Results There were 196 cases in which p16 testing was performed in a period of 3 consecutive years. Of these, 175 were FNA/ biopsies and 21 were surgical resections. In 69 cases (56 FNAs and 13 biopsies) the biopsy was performed on neck masses with unknown primary. The compliance for p16 testing in OPC and Lymph nodes with metastatic SCC of unknown primary was 100%. In 34 (17.3%) cases p16 testing was not indicated, the most common reason being wrong site (85%) including the larynx, oral tongue, the floor of the mouth, buccal mucosa, and nasal mass. Of the unindicated p16s, 20 (58%) were received in consultation for continuity of care. Conclusion Not being clear about the site of the tumor is the most common reason for unindicated p16 testing. A clear designation of biopsy site and proper communication between pathologist and surgeon can improve utilization of p16 testing in head and neck carcinomas.

The role of microsatellite instability in cervical intraepithelial neoplasia and squamous cell carcinoma of the cervix

2003 ◽  
Vol 89 (3) ◽  
pp. 434-439 ◽  
Author(s):  
Yick-Fu Wong ◽  
Tak-Hong Cheung ◽  
Kin-Yan Poon ◽  
Vivian Wei Wang ◽  
James C.B Li ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Microsatellite Instability ◽  
Cell Carcinoma ◽  
Cervical Intraepithelial Neoplasia ◽  
Squamous Cell ◽  
Intraepithelial Neoplasia

CDX2 Is a Useful Marker of Intestinal-Type Differentiation: A Tissue Microarray–Based Study of 629 Tumors From Various Sites

2005 ◽  
Vol 129 (9) ◽  
pp. 1100-1105 ◽  
Author(s):  
Lindsey B. De Lott ◽  
Carl Morrison ◽  
Saul Suster ◽  
David E. Cohn ◽  
Wendy L. Frankel
Keyword(s):  
Squamous Cell ◽  
Signet Ring Cell ◽  
Squamous Cell Carcinomas ◽  
Intestinal Type ◽  
High Grade ◽  
Poorly Differentiated Neuroendocrine Carcinoma ◽  
Poorly Differentiated ◽  
Lung Adenocarcinomas ◽  
Colorectal Adenocarcinomas ◽  
Neuroendocrine Carcinomas

Abstract Context.—CDX2, a critical nuclear transcription factor for intestinal development, is expressed in intestinal epithelium and adenocarcinomas. Objectives.—To determine if CDX2 is a useful marker for intestinal-type differentiation and to correlate tumor histology with CDX2 staining in colorectal adenocarcinomas. Design.—Tissue microarrays from 71 colorectal adenocarcinomas, 31 hepatocellular carcinomas, 47 lung adenocarcinomas, 55 squamous cell carcinomas of the lung, 69 neuroendocrine carcinomas of the lung and 43 of the pancreas, 57 pancreatic adenocarcinomas, and 256 endometrial adenocarcinomas were stained with antibody against CDX2. Results.—CDX2 staining was positive in 51 (71.8%) of 71 colorectal cancers, including 38 (74.5%) of 51 well- or moderately differentiated tumors and 13 (65.0%) of 20 high-grade tumors. Of the high-grade tumors, 5 (71.4%) of 7 mucinous, 3 (100%) of 3 signet ring cell, and 5 (50.0%) of 10 poorly differentiated tumors were positive. Other tumors showing occasional CDX2 staining included 1 of 30 well- or moderately differentiated neuroendocrine carcinomas of the lung and 2 of 43 from the pancreas, 1 of 47 lung adenocarcinomas, 3 of 57 pancreatic adenocarcinomas, and 15 of 256 endometrial carcinomas. Hepatocellular, poorly differentiated neuroendocrine carcinoma of the lung and squamous cell carcinomas of the lung were not immunoreactive for CDX2. Conclusions.—CDX2 is a useful marker for intestinal-type differentiation, is rarely seen in tumors from the other sites evaluated, and may be useful in determining the site of origin for some metastatic tumors. However, CDX2 is not a sensitive marker for poorly differentiated colorectal carcinoma.

Sign in / Sign up

Export Citation Format

Share Document